Výnosy Q/Q spoločnosti Hutchison China MediTech

Aká je hodnota metriky Výnosy Q/Q spoločnosti Hutchison China MediTech?

Hodnota metriky Výnosy Q/Q spoločnosti Hutchison China MediTech Ltd. je -42.64%

Aká je definícia metriky Výnosy Q/Q?

Štvrťročný rast výnosov (Revenue Q/Q) z roku na rok je zvýšenie príjmov firmy v porovnaní s výsledkami v korešpondujúcom štvrťroku minulého roku a vyjadreného v percentách.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Čomu sa venuje spoločnosť Hutchison China MediTech?

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Firmy s metrikou výnosy q/q podobnou spoločnosti Hutchison China MediTech

  • Hodnota metriky Výnosy Q/Q spoločnosti Venzee Technologies je -42.73%
  • Hodnota metriky Výnosy Q/Q spoločnosti Stereotaxis je -42.72%
  • Hodnota metriky Výnosy Q/Q spoločnosti Riba Textiles je -42.69%
  • Hodnota metriky Výnosy Q/Q spoločnosti Bega Cheese je -42.68%
  • Hodnota metriky Výnosy Q/Q spoločnosti Nagreeka Exports je -42.67%
  • Hodnota metriky Výnosy Q/Q spoločnosti Bowl America je -42.67%
  • Hodnota metriky Výnosy Q/Q spoločnosti Hutchison China MediTech je -42.64%
  • Hodnota metriky Výnosy Q/Q spoločnosti Startek je -42.61%
  • Hodnota metriky Výnosy Q/Q spoločnosti Integrated Diagnostics plc je -42.57%
  • Hodnota metriky Výnosy Q/Q spoločnosti iSentric je -42.50%
  • Hodnota metriky Výnosy Q/Q spoločnosti Skyline je -42.50%
  • Hodnota metriky Výnosy Q/Q spoločnosti 51 Credit Card je -42.44%
  • Hodnota metriky Výnosy Q/Q spoločnosti Broo je -42.42%